Releases
8. March, 2022
Successful outcome from trial 0204
Cessatech reports successful outcome of bioavailability trial 0204 Topline results of clinical trial 0204...
Releases
3. March, 2022
Annual report 2021 published
Cessatech A/S publishes its annual report for the fiscal year 2021. “We managed to...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Releases
6. January, 2022
Changes to the Board of Directors – welcome to Rachel
Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...
Releases
22. December, 2021
Cessatech successfully raises DKK 24.3 million through warrant exercise
During the period 25 November – 16 December 2021, holders of TO 1 have...
Releases
25. November, 2021
Exercise warrants of series TO1 before 14 Dec
In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and...
Releases
2. November, 2021
First US patent covering CT001
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799...
Media
23. September, 2021
#FEMSNABBA…
https://borsvarlden.com/artiklar/Fem-fr%C3%A5gor-till-Jes-Trygved?fbclid=IwAR0sa-omHrXpxrvnQd87xFDRDWZzVQQsIEr6VH9aY7S8BkLbXNzhL6AnShI
Releases
20. August, 2021
Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate
Clinical trial 0206 will investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical...
Releases
19. August, 2021
Second quarter report Q2-2021 – planning for the pivotal trials
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...
Releases
29. June, 2021
Cessatech announces new Chairman of the Board – getting ready for the pivotal studies
The Board of Directors has appointed Adam Steensberg as new Chairman of the...
Releases
31. May, 2021
Last subject dosed in bioavailability trial 0204 of lead product candidate
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...